Eagle’s Eye View: Racial Differences in SGLT2i Treatments

In this week’s View, Dr. Eagle explores the association of successful percutaneous revascularization of chronic total occlusions with quality of life. He then discusses the feasibility and safety of flecainide use among patients with varying degrees of coronary disease. Finally, Dr. Eagle looks at an incredibly important meta-analysis on the racial differences in quality of life among patients with heart failure who are treated with sodium-glucose cotransporter 2 inhibitors.

Twitter Links:

Clinical Topics: Arrhythmias and Clinical EP, Cardiac Surgery, Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Atherosclerotic Disease (CAD/PAD), Implantable Devices, EP Basic Science, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Aortic Surgery, Cardiac Surgery and Arrhythmias, Cardiac Surgery and Heart Failure, Cardiac Surgery and SIHD, Lipid Metabolism, Acute Heart Failure, Interventions and Coronary Artery Disease, Acute Coronary Syndromes

Keywords: Angina Pectoris, Chronic Disease, Coronary Occlusion, Exercise Tolerance, Myocardial Ischemia, Myocardial Revascularization, Percutaneous Coronary Intervention, Quality of Life, Secondary Prevention, Anti-Arrhythmia Agents, Arrhythmias, Cardiac, Atrial Fibrillation, Coronary Artery Disease, Flecainide, Heart Failure, Myocardial Infarction, Survival, Tachycardia, Ventricular, African Americans, Health Status, Health Status Disparities, Metabolic Syndrome, Race Factors, Sodium-Glucose Transporter 2 Inhibitors, Sodium-Glucose Transporter 2, Stroke Volume, Stroke Volume, EaglesEyeView

< Back to Listings